Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
48 Results for "
tumor volume
" in MedChemExpress (MCE) Product Catalog:
Products (48)
48 Results for "tumor volume" in MCE Product Catalog:
11
11 Publications Verification
Cat. No.: HY-13535
CAS No.: 262438-43-7
Research Areas:
Cardiovascular Disease Infection Neurological Disease Cancer
ATN-161 is an antagonist of α5β1 integrin and αvβ3 integrin, as well as an inhibitor of fibrosis, an inhibitor of oxidative stress, a tight junction stabilizer, a mitochondrial integrity protector, an angiogenesis inhibitor and an antiviral agent. ATN-161 inhibits NLRP3, MAPK, and ROS. ATN-161 protects mice from SARS-CoV-2 infection . ATN-161 reduces infarct volume, alleviates edema, decreases immune cell infiltration, reduces the area of choroidal neovascularization lesions, lowers tumor microvessel density and viral load. ATN-161 can be used in research related to ischemic stroke, choroidal neovascularization, breast cancer, coronavirus disease 2019 (COVID-19), and liver metastasis of colorectal cancer .
3
Target:
Research Areas:
2
2 Cited Publications
Cat. No.: HY-P10102
CAS No.: 629628-53-1
1
1 Cited Publications
Cat. No.: HY-168374
CAS No.: 1829524-73-3
Research Areas:
DSPE-PEG 2000-Mannose is a mannose-containing lipid. DSPE-PEG 2000-Mannose is used to prepare mannose-conjugated Liposome (Man-lipo) for siRNA delivery. Mannose-modified liposomes encapsulating IDO siRNA (Man-lipo-siIDO) preferentially knock down IDO expression in the draining lymph nodes and spleens of melanoma-bearing mice. Man-lipo-siIDO delays the onset time of melanoma and reduces tumor volume .
1
1 Cited Publications
BCI-137 is a Argonaute 2 (AGO2) inhibitor. By inhibiting AGO2 function, reducing PTPN6/SHP-1 protein levels and enhancing STAT1 phosphorylation, BCI-137 restores the sensitivity of tumor cells to IFN-γ. BCI-137 effectively enhances the recruitment, activation and cytotoxicity of CD8 + T cells. BCI-137 exerts a synergistic effect with anti-PD-1 antibodies and significantly reduces tumor volume in preclinical mouse models. BCI-137 exhibits favorable safety profiles and does not cause significant weight loss or death in mice. BCI-137 can be used in research related to bladder cancer, colorectal cancer, melanoma and other related fields .
1
Research Areas:
Sodium metavanadate, 99% (Sodium vanadate (V), 99%) is an orally active phosphate structural analog and protein tyrosine phosphatase (PTPases) inhibitor. Sodium metavanadate, 99% mimics phosphate to interfere with phosphoprotein reactions, inhibits GAPDH, Na +/K +-ATPase and microbial membrane ATPase, and acts as a terminal electron acceptor for anaerobic respiration. Sodium metavanadate, 99% induces ROS production, G2/M phase arrest, mitochondrial membrane potential loss and apoptosis in breast cancer cells, and reduces tumor volume in tumor-bearing mice. Sodium metavanadate, 99% also exhibits oral insulin-sensitizing and metabolic regulatory activities, and reduces plasmodium parasitemia levels. Sodium metavanadate, 99% can be used in studies related to cadmium exposure-induced metabolic syndrome, plasmodium infection, breast cancer and type 1 diabetes .
1
1 Cited Publications
Cat. No.: HY-148775B
Purity: ≥95.0%
Target:
Research Areas:
PLGA-PEG-MAL (20KDA-5.0KDA, LA:GA RATIO 40:60) is a biodegradable amphipathic polymeric nanocarrier of poly (lactic-co-glycolic acid)-block-poly (ethylene glycol) (PLGA-PEG-Mal) that allows covalent modification of functional molecules. PLGA-PEG-MAL (20KDA-5.0KDA, LA:GA RATIO 40:60) modified with Angiopep-2 can cross the blood-brain barrier and exhibits targeting selectivity for glioblastoma cells. PLGA-PEG-MAL (20KDA-5.0KDA, LA:GA RATIO 40:60) can capture tumor-derived protein antigens, and exerts immunomodulatory effects when conjugated with anti-OX40 antibody; when used in combination with A2-CL/Dbait nanoparticles and radiotherapy, it prolongs survival time and reduces tumor volume in glioblastoma mouse models. PLGA-PEG-MAL (20KDA-5.0KDA, LA:GA RATIO 40:60) can be used for studies related to bacterial wound infections and glioblastoma .
Target:
Research Areas:
FTI 276 TFA is a farnesyltransferase (FTase) inhibitor with an IC50 of 0.5 nM, and it exhibits selectivity for FTase over geranylgeranyltransferase I (GGTase I). FTI 276 TFA blocks the farnesylation of H-Ras and K-Ras4B, causes inactive Ras-Raf complexes to accumulate in the cytoplasm, and inhibits constitutive MAPK activation. FTI 276 TFA reduces the number, incidence and volume of tumors, and restricts the growth of tumors expressing activated K-ras. FTI 276 TFA can be used in research related to pulmonary adenoma .
Cat. No.: HY-P11287A
Research Areas:
Target:
Research Areas:
HTS07545 is a sulfide:quinone oxidoreductase (SQOR) inhibitor with an IC50 of 30 nM. HTS07545 inhibits SQOR function and mediates resistance to ferroptosis. HTS07545 reduces tumor volume and weight of pancreatic ductal adenocarcinoma. HTS07545 induces tumor cell nuclear necrosis. The combination of HTS07545 and Erastin (HY-15763) exerts a synergistic effect without causing significant weight loss in mice. HTS07545 can be used in studies related to pancreatic ductal adenocarcinoma and heart failure [1] [2].
Cat. No.: HY-148775A
CAS No.: 743423-15-6
Target:
Research Areas:
MPEG-PLGA (21500-26500) is a biodegradable amphipathic polymeric nanocarrier of poly (lactic-co-glycolic acid)-block-poly (ethylene glycol) (PLGA-PEG-Mal) that allows covalent modification of functional molecules. MPEG-PLGA (21500-26500) modified with Angiopep-2 can cross the blood-brain barrier and exhibits targeting selectivity for glioblastoma cells. MPEG-PLGA (21500-26500) can capture tumor-derived protein antigens, and exerts immunomodulatory effects when conjugated with anti-OX40 antibody; when used in combination with A2-CL/Dbait nanoparticles and radiotherapy, it prolongs survival time and reduces tumor volume in glioblastoma mouse models. MPEG-PLGA (21500-26500) can be used for studies related to bacterial wound infections and glioblastoma .
Cat. No.: HY-N1510
CAS No.: 22149-35-5
Cat. No.: HY-DY1021
CAS No.: 53213-94-8
Solvent and concentration: DMSO: 1 mM
The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.
Target:
Research Areas:
KDM5B-IN-4 (compound 11ad) is a lysine demethylase 5B (KDM5B) inhibitor with an IC50 of 0.025 μM KDM5B-IN-4 increases substrate H3K4me1/2/3 level by inhibiting KDM5B in PC-3 cells. KDM5B-IN-4 downregulates PI3K/AKT. KDM5B-IN-4 reduces tumor volume in mice and shows less toxic to organs .
Research Areas:
JS-K is a NO donor that reacts with glutathione to generate NO at physiological pH. JS-K induces reactive oxygen species (ROS) to mediate apoptosis. JS-K induces autophagy. JS-K inhibits invasion. JS-K has a broad spectrum anti-proliferative activity in cancer cells. JS-K reduces tumor volume and causes necrosis of implanted tumors in mice .
Cat. No.: HY-177083
CAS No.: 1841402-73-0
Synonyms: AVA-6000
Faridoxorubicin (AVA-6000) is a FAP-activated chemotherapeutic prodrug. Faridoxorubicin undergoes selective hydrolysis by FAP, while it is resistant to cleavage by related mammalian peptidases and members of the DASH subfamily. Faridoxorubicin acts as a tumor growth inhibitor, reducing tumor volume and prolonging survival in in vivo models and PDX models with high FAP expression. Faridoxorubicin can be used in the research of osteosarcoma and sarcoma .
Cat. No.: HY-P4144
CAS No.: 1174415-90-7
Synonyms: Phor18-LHRH (338613); EP-100
Target:
Research Areas:
Cat. No.: HY-143321
CAS No.: 2816929-48-1
STING agonist-13 is a stimulator of interferon genes (STING) agonist, for cancer immunity via STING-mediated immune activation. STING agonist-13 can stimulate STING downstream signaling and promoting type I interferon immune responses. STING agonist-13 significantly decreases tumor volume and shows immunological memory-derived cancer inhibition .
Cat. No.: HY-148775
Purity: ≥95.0%
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
